A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
March 17, 2022 09:00 ET | JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...
Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease
January 27, 2022 09:00 ET | Enterin Inc.
PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
January 26, 2022 02:55 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease
January 25, 2022 09:00 ET | Enterin Inc.
PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
January 11, 2022 15:00 ET | Enterin Inc.
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center
January 11, 2022 13:10 ET | CenExel Clinical Research
Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site...
Enterin Announces Appointment of Dr. Patrik Brundin to Its Scientific Advisory Board
January 10, 2022 09:00 ET | Enterin Inc.
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
January 04, 2022 07:30 ET | Cognition Therapeutics, Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021
December 10, 2021 11:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy
October 11, 2021 07:00 ET | Amydis, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...